Can a patient who refuses rivaroxaban (Xarelto) be prescribed apixaban (Eliquis) as an alternative anticoagulant?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, Eliquis (apixaban) is an appropriate and often preferred alternative when a patient refuses Xarelto (rivaroxaban).

Both apixaban and rivaroxaban are FDA-approved direct oral anticoagulants (DOACs) that can be used interchangeably for most anticoagulation indications, and switching between them based on patient preference is clinically reasonable and commonly done. 1

Why Apixaban May Actually Be the Better Choice

The most recent evidence suggests apixaban may offer superior outcomes compared to rivaroxaban:

  • Lower bleeding risk: A 2026 meta-analysis of over 220,000 VTE patients found apixaban reduced major bleeding by 28% compared to rivaroxaban (RR 0.72; 95% CI 0.65-0.81) 2

  • Reduced recurrent thrombosis: The same study showed apixaban decreased recurrent VTE by 15% (RR 0.85; 95% CI 0.74-0.98) 2

  • Better net clinical benefit: When combining efficacy and safety, apixaban demonstrated 24% lower net clinical harm (RR 0.76; 95% CI 0.68-0.86) 2

  • Lower mortality in atrial fibrillation: A large Medicare study of 581,451 patients found rivaroxaban increased the composite of major ischemic/hemorrhagic events by 18% (HR 1.18; 95% CI 1.12-1.24) and total mortality by 6% (HR 1.06; 95% CI 1.02-1.09) compared to apixaban 3

Guideline Support

The 2026 ACC Scientific Statement specifically recommends apixaban as the preferred DOAC in certain high-risk populations including frail patients and those with prior bleeding history, citing its consistent benefit and lower bleeding risk 4. For patients with obesity (BMI ≥40), both rivaroxaban and apixaban are appropriate options 4.

Practical Prescribing Considerations

Dosing differs between the two agents 5:

  • Apixaban: 10 mg twice daily × 7 days, then 5 mg twice daily (for VTE); 5 mg twice daily for atrial fibrillation
  • Rivaroxaban: 15 mg twice daily × 21 days, then 20 mg once daily (for VTE); 20 mg once daily for atrial fibrillation

Dose reductions for apixaban (2.5 mg twice daily) apply when ≥2 of the following: age ≥80 years, serum creatinine ≥1.5 mg/dL, or weight ≤60 kg 5

Key pharmacokinetic advantage: Apixaban has more predictable absorption (food-independent, linear pharmacokinetics) compared to rivaroxaban (food-dependent, dissolution-limited absorption in proximal GI tract), making it more reliable in patients with GI issues 6

Critical Safety Points

When switching from rivaroxaban to apixaban 1:

  • Do not leave a gap in anticoagulation - start apixaban when the next rivaroxaban dose would have been due
  • Warn about premature discontinuation risk - stopping any DOAC without alternative coverage increases thrombotic risk
  • Counsel on bleeding signs - both agents increase bleeding risk; patients need clear instructions on when to seek emergency care
  • Check renal function - both require dose adjustment for CrCl 15-50 mL/min; apixaban is preferred if CrCl <30 mL/min as rivaroxaban should be avoided 5

Common Pitfalls to Avoid

  • Don't overlap with parenteral anticoagulation unless treating acute VTE requiring lead-in dosing
  • Don't use in mechanical heart valves - neither DOAC is approved for this indication 1
  • Avoid in severe hepatic impairment (Child-Pugh C)
  • Be cautious with neuraxial procedures - wait 24 hours after last apixaban dose before catheter removal; wait 5 hours after catheter removal before next dose 1

The patient's refusal of rivaroxaban actually presents an opportunity to prescribe what may be the superior agent based on current evidence.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.